文献速递神经肌肉病

认知行为治疗联合可选分级运动治疗对1型强直性肌营养不良伴严重疲劳患者的影响:一项多中心、单盲、随机试验

Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.
PubMed 文献 · Lancet Neurol · 2018-06-19

这项多中心单盲随机试验纳入255例伴严重疲劳的1型强直性肌营养不良患者,比较认知行为治疗联合标准治疗(可选分级运动)与单纯标准治疗。10个月时DM1-Activ-c评分组间平均差异为3.27分(95%CI 0.93-5.62,p=0.007),认知行为治疗组活动与社会参与能力改善。作者认为可考虑用于严重疲劳患者。

要点

  • 认知行为治疗组DM1-Activ-c评分从基线61.22分升至10个月63.92分。
  • 标准治疗组评分从63.00分降至10个月60.79分。
  • 组间平均差异3.27分(95%CI 0.93-5.62,p=0.007),支持认知行为治疗。

核心结论

  • 认知行为治疗提高了1型强直性肌营养不良患者10个月时的活动能力和社会参与能力。
  • 在无治愈性治疗且对症治疗有限的情况下,作者认为可考虑将认知行为治疗用于伴严重疲劳的1型强直性肌营养不良患者。

研究设计与样本

  • 多中心、单盲、随机试验,在巴黎(法国)、慕尼黑(德国)、奈梅亨(荷兰)和纽卡斯尔(英国)四个神经肌肉转诊中心进行。
  • 纳入18岁及以上、经基因确诊的1型强直性肌营养不良且严重疲劳(个体力量检查清单疲劳亚量表评分≥35分)的患者。
  • 按1:1随机分配至认知行为治疗联合标准治疗及可选分级运动组或单纯标准治疗组,通过中央网络系统随机化并按研究中心分层。
  • 认知行为治疗为期10个月,共10-14次 sessions;分级运动模块可在奈梅亨和纽卡斯尔加入。
  • 主要结局为DM1-Activ-c量表(评分范围0-100)从基线至10个月的变化,使用混合效应线性回归模型并以基线评分为协变量。

主要发现

  • 2014年4月2日至2015年5月29日随机分配255例患者:128例至认知行为治疗联合标准治疗组,127例至单纯标准治疗组。
  • 认知行为治疗组中33例(26%)同时接受了分级运动模块。
  • 认知行为治疗组DM1-Activ-c评分从基线平均(SD)61.22(17.35)分升至10个月63.92(17.41)分,调整后平均差异1.53(95%CI -0.14至3.20)。
  • 标准治疗组评分从63.00(17.35)分降至60.79(18.49)分,平均差异-2.02(95%CI -4.02至-0.01)。
  • 组间平均差异为3.27分(95%CI 0.93至5.62,p=0.007)。

关键数值与推荐

  • 严重疲劳定义为个体力量检查清单疲劳亚量表评分≥35分。
  • 主要结局DM1-Activ-c评分范围0-100分。
  • 认知行为治疗疗程为10个月,共10-14次 sessions。

临床怎么用

  • 作者认为,在无治愈性治疗且对症治疗有限的情况下,可考虑将认知行为治疗用于伴严重疲劳的1型强直性肌营养不良患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myotonic dystrophy type 1 is the most common form of muscular dystrophy in adults and leads to severe fatigue, substantial physical functional impairment, and restricted social participation. In this study, we aimed to determine whether cognitive behavioural therapy optionally combined with graded exercise compared with standard care alone improved the health status of patients with myotonic dystrophy type 1. METHODS: We did a multicentre, single-blind, randomised trial, at four neuromuscular referral centres with experience in treating patients with myotonic dystrophy type 1 located in Paris (France), Munich (Germany), Nijmegen (Netherlands), and Newcastle (UK). Eligible participants were patients aged 18 years and older with a confirmed genetic diagnosis of myotonic dystrophy type 1, who were severely fatigued (ie, a score of ≥35 on the checklist-individual strength, subscale fatigue). We randomly assigned participants (1:1) to either cognitive behavioural therapy plus standard care and optional graded exercise or standard care alone. Randomisation was done via a central web-based system, stratified by study site. Cognitive behavioural therapy focused on addressing reduced patient initiative, increasing physical activity, optimising social interaction, regulating sleep-wake patterns, coping with pain, and addressing beliefs about fatigue and myotonic dystrophy type 1. Cognitive behavioural therapy was delivered over a 10-month period in 10-14 sessions. A graded exercise module could be added to cognitive behavioural therapy in Nijmegen and Newcastle. The primary outcome was the 10-month change from baseline in scores on the DM1-Activ-c scale, a measure of capacity for activity and social participation (score range 0-100). Statistical analysis of the primary outcome included all participants for whom data were available, using mixed-effects linear regression models with baseline scores as a covariate. Safety data were presented as descriptives. This trial is registered with ClinicalTrials.gov, number NCT02118779. FINDINGS: Between April 2, 2014, and May 29, 2015, we randomly assigned 255 patients to treatment: 128 to cognitive behavioural therapy plus standard care and 127 to standard care alone. 33 (26%) of 128 assigned to cognitive behavioural therapy also received the graded exercise module. Follow-up continued until Oct 17, 2016. The DM1-Activ-c score increased from a mean (SD) of 61·22 (17·35) points at baseline to 63·92 (17·41) at month 10 in the cognitive behavioural therapy group (adjusted mean difference 1·53, 95% CI -0·14 to 3·20), and decreased from 63·00 (17·35) to 60·79 (18·49) in the standard care group (-2·02, -4·02 to -0·01), with a mean difference between groups of 3·27 points (95% CI 0·93 to 5·62, p=0·007). 244 adverse events occurred in 65 (51%) patients in the cognitive behavioural therapy group and 155 in 63 (50%) patients in the standard care alone group, the most common of which were falls (155 events in 40 [31%] patients in the cognitive behavioural therapy group and 71 in 33 [26%] patients in the standard care alone group). 24 serious adverse events were recorded in 19 (15%) patients in the cognitive behavioural therapy group and 23 in 15 (12%) patients in the standard care alone group, the most common of which were gastrointestinal and cardiac. INTERPRETATION: Cognitive behavioural therapy increased the capacity for activity and social participation in patients with myotonic dystrophy type 1 at 10 months. With no curative treatment and few symptomatic treatments, cognitive behavioural therapy could be considered for use in severely fatigued patients with myotonic dystrophy type 1. FUNDING: The European Union Seventh Framework Programme.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Okkersen K, Jimenez-Moreno C, Wenninger S, et al. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurol. 2018. PMID: 29934199. doi:10.1016/S1474-4422(18)30203-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。